Results 181 to 190 of about 9,804 (228)

Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease. [PDF]

Nat Commun
Rothhaar P, Arand T, Seong HG, Heuss C, Tulessin M, Wang Z, Förster C, Schneider AC, Quistrebert J, Chai H, Reineke M, Benning L, Honegger J, Hofmann M, Thimme R, Timm J, STOPHCV investigators, Schnitzler P, Merle U, Shoukry NH, Bruneau J, Rodrigo C, Lloyd A, Bull RA, Ansari MA, Mogler C, McLauchlan J, Forns X, Pérez-Del-Pulgar S, Lohmann V.   +29 more
europepmc   +1 more source

Strategies of Classical Swine Fever Immune Evasion. [PDF]

Int J Mol Sci
Zhang Y, Li F, Liu Y.
europepmc   +1 more source

Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies. [PDF]

Syst Rev
Kumburegama BWMB, Kristensen AT, Bjelakovic G, Nikolova D, Asante MA, Bjelakovic M, Koretz RL, Balakumar MM, Michelsen ME, Klingenberg SL, Gluud C.   +10 more
europepmc   +1 more source

Tracking the evolution of multiple in vitro HCV replicon mutants under protease inhibitor selection pressure by 454 ultra deep sequencing. [PDF]

Claes, Marijke, Fanning, G, Lenz, O, Neyts, Johan, Simmen, K, Van Marck, H, Vandenbroucke, I, Verbinnen, T, Vijgen, L   +8 more
core  

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study. [PDF]

Viruses
Yoon JH, Lee CH, Jo HG, Cho JY, Kim JD, Kim JW, You GR, Cho SB, Choi SK.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Biochemical and Biophysical Research Communications, 2018
Patients with chronic hepatitis C virus (HCV) infection who have failed to respond to direct-acting antiviral (DAA) treatment often acquire drug resistance-associated variants (RAVs). The NS5A-P32 deletion (P32del) RAV confers potent resistance to NS5A inhibitors; therefore, patients who acquire this deletion are likely to fail to respond to DAA re ...
Yuji Teraoka, Takuro Uchida, Michio Imamura, Mitsutaka Osawa, Masataka Tsuge, Hiromi Abe-Chayama, C. Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama   +13 more
openaire   +4 more sources

NS5A Inhibitors

Current Hepatitis Reports, 2012
As a result of rapid advance medicinal chemistry, the time frame 2011–2012 has been an exciting one that has witnessed the release of the first direct acting antiviral agents (DAA). Multiple enzymatic and protein regions of the virus can serve as targets for these new drugs. One of the newest and most promising of these targets is the NS5A protein. The
Christopher O’Brien, Nicholas Agresti
openaire   +1 more source

HCV NS5A replication complex inhibitors

Current Opinion in Pharmacology, 2016
The development of anti-HCV drugs is one of the most successful stories of antiviral therapy. In fact, for the first time in human history we have the potential to eradicate a chronic viral infection using only orally administered direct antiviral agents (DAAs).
Min, Gao, Donald R, O'Boyle, Susan, Roberts   +2 more
openaire   +2 more sources

Discovery of fluorobenzimidazole HCV NS5A inhibitors

Bioorganic & Medicinal Chemistry Letters, 2016
Research toward a next-generation HCV NS5A inhibitor has identified fluorobenzimidazole analogs that demonstrate potent, broad-genotype in vitro activity against HCV genotypes 1-6 replicons as well as HCV NS5A variants that are orders of magnitude less susceptible to inhibition by first-generation NS5A inhibitors in comparison to wild-type replicons ...
John T, Randolph, Charles A, Flentge, Pamela, Donner, Todd W, Rockway, Sachin V, Patel, Lissa, Nelson, Douglas K, Hutchinson, Rubina, Mondal, Neeta, Mistry, Thomas, Reisch, Tatyana, Dekhtyar, Preethi, Krishnan, Tami, Pilot-Matias, Deanne F, Stolarik, David W A, Beno, Rolf, Wagner, Clarence, Maring, Warren M, Kati   +17 more
openaire   +2 more sources

The NS5A Replication Complex Inhibitors: Difference Makers?

Clinics in Liver Disease, 2011
The development and approval of direct-acting antiviral agents looks set to transform the treatment of chronic hepatitis C infection. Among the agents in development are novel compounds that inhibit the function of the NS5A protein: a pleiotropic protein with a complex and essential role in viral replication.
Robert G, Gish, Nicholas A, Meanwell
openaire   +2 more sources